Pulmonary Arterial Hypertension in Connective Tissue Disease: Improving Awareness, Screening, and Management

Released On
May 6, 2021

Expires On
May 6, 2022

Media Type
Internet

Completion Time
60 minutes

Specialty
Cardiology, Education, Primary Care

Topic(s)
Cardiovascular Disease, Respiratory

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Practicing Clinicians Exchange (PCE) in partnership with the Association of Pulmonary Advanced Practice Providers and the Society of Physician Assistants in Rheumatology.

Supported by an educational grant from Actelion Pharmaceuticals US, Inc..

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours includes 1.00 hour of pharmacology credit.
  • Physician Assistants — 1.00 AAPA Category 1 CME credit.

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

Cardiologists, rheumatologists, pulmonologists, and NPs and PAs specializing in cardiology, rheumatology, and pulmonology.

Statement of Need/Program Overview

Thanks to improvements in therapies and management, survival for patients with pulmonary arterial hypertension (PAH) has improved over the last 20 years. Unfortunately, patients with PAH and connective tissue disease (CTD)—especially systemic sclerosis—have not matched these outcomes. What is your role in closing this gap, even if you are not in a pulmonary hypertension specialty center? In this video roundtable, three experts in rheumatology and pulmonary medicine give you front-row access to their discussions on how rheumatology, pulmonology, and cardiology physicians, NPs, and PAs can collaborate to recognize and manage PAH early in this crucial patient population.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify the symptoms and signs of CTD-PAH and the screening tools needed to refer patients for further evaluation and prompt initiation of treatment
  • Describe current recommendations for the management of PAH and how they should be tailored to patients with CTD

Faculty

FACULTY_NAME

Martha Kingman, FNP-C, DNP

Nurse Practitioner
Pulmonary Hypertension Clinic
University of Texas Southwestern Medical Center
Dallas, Texas

FACULTY_NAME

Virginia Steen, MD

Professor of Medicine
Georgetown University Medical Center
Chief of Rheumatology
MedStar Georgetown University Hospital
Georgetown University
Washington, DC

FACULTY_NAME

Victor F. Tapson, MD

Professor of Medicine
Associate Director
Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, California
Past President
US Pulmonary Embolism Response Team Consortium

Joint Accreditation Statement

In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation

Practicing Clinicians Exchange designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Designates 1.00 contact hours, which includes 1.00 hour of pharmacology credit.

AAPA Credit Designation

In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

PA course advisor: Daniel Thibodeau, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia

Disclosures of Conflicts of Interest

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Kingman: advisory board/consultant: Actelion/Johnson & Johnson, Bayer, United Therapeutics.

Dr Steen: advisory board/consultant: Boehringer Ingelheim; Eicos; speakers bureau: Actelion/Janssen, Johnson & Johnson.

Dr Tapson: advisory board/consultant/research: Bayer, Bristol Myers Squibb, EKOS/BTG/Boston Scientific, Johnson & Johnson/Actelion/Janssen, Penumbra, United Therapeutics; advisory board: Thrombolex; speakers bureau: EKOS/BTG/Boston Scientific, Janssen.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Submit the evaluation form.
Certificates will be emailed to the participant

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Contact Information

For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com